To investigate whether ShcD expression modulates the drug sensitivity of melanoma cells, MM27 PDX cells, carrying the BRAFV600E mutation, were transduced with ShLuc and ShShcD vectors and treated with Dabrafenib (BRAF inhibitor), Trametinib (MEK inhibitor) or Everolimus (mTOR inhibitor). The gene discussed is MAP2K7; the disease is melanoma.